Guidelines for the prophylaxis of haemophilia A and B: new horizons and ambitions

Affiliations

Comment

Cedric Hermans. Br J Haematol. 2020 Sep.

. 2020 Sep;190(5):643-644.

doi: 10.1111/bjh.16698. Epub 2020 Apr 30.

¹ Division of Hematology, Hemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belgium.

No abstract available

Keywords: guideline; haemophilia; prophylaxis.

Comment on

Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B.
Rayment R, Chalmers E, Forsyth K, Gooding R, Kelly AM, Shapiro S, Talks K, Tunstall O, Biss T; British Society for Haematology. Rayment R, et al. Br J Haematol. 2020 Sep;190(5):684-695. doi: 10.1111/bjh.16704. Epub 2020 May 10. Br J Haematol. 2020. PMID: 32390158 Review. No abstract available.

1. Khair K, Mazzucconi MG, Parra R, Santagostino E, Tsakiris DA, Hermans C, et al. Pattern of bleeding in a large prospective cohort of haemophilia A patients: a three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study. Haemophilia. 2018;24:85-96.
1. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125:2038-44.
1. Rayment R, Chalmers E, Forsyth K, Gooding R, Kelly AM, Shapiro S, et al. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. A British Society for Haematology Guideline. 2020;190:684-95.
1. Butterfield JS, Hege KM, Herzog RW, Kaczmarek R. A molecular revolution in the treatment of hemophilia. Mol Ther. 2020;28:997-1015.
1. Mannucci PM. Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A. Expert Opin Investig Drugs. 2020;29:303-9.